Sandoz, the Novartis subsidiary dedicated to generic and biosimilar drugs, announced the signing of an agreement for the construction of a new biomedicine production plant in Lendava, Slovenia, where the group is already established. For this project, the laboratory plans to invest an envelope of 400 million dollars (378 M€).
VOS INDICES
source
“This investment underscores our ambition to be the enduring global leader in biosimilar medicines, a business area that is expected to experience double-digit annual growth over the next decade.”said Richard Saynor, CEO of Sandoz.
Work on this new plant should begin this year, with completion scheduled for the end of 2026. In addition to Lendava, Sandoz has other sites in Slovenia, in Ljubljana, Menges and Prevalje.
This investment demonstrates Sandoz’s desire to expand its production network in Europe, as the subsidiary is set to separate from its parent company Novartis this year.
In November 2022, Sandoz announced a €50 million investment in Austria to increase its penicillin production, bringing the amount invested in its facilities to €250 million over the past two years.
Selected for you
